Cidara Therapeutics, Inc. - Common Stock, $0.0001 par value per share (CDTX)

Historical Holders from Q2 2024 to Q4 2025

Type / Class
Equity / Common Stock, $0.0001 par value per share
Symbol
CDTX on Nasdaq
Shares outstanding
31,522,645
Price per share
$220.89
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares as of 30 Sep 2025
32,486,735
Total reported value
$3,110,319,924
% of total 13F portfolios
0.01%
Share change
+6,511,648
Value change
+$679,671,203
Avg buy value change
+0%
Avg sell value change
-0%
Number of holders
167
Price from insider filings
$221.50
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Cidara Therapeutics, Inc. - Common Stock, $0.0001 par value per share (CDTX) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BCLS Fund III Investments, LP 10% 0% $289,290,002 +$49,824,886 3,020,990 +21% BCLS Fund III Investments, LP 30 Sep 2025
Point72 Asset Management, L.P. 6.2% -18% $151,115,887 +$4,801,311 1,578,069 +3.3% Point72 Asset Management, L.P. 30 Sep 2025
BIOTECHNOLOGY VALUE FUND L P 4.4% -16% $113,871,586 -$21,545,460 1,189,165 -16% BVF PARTNERS L P/IL 15 Oct 2025
Vivo Opportunity Fund Holdings, L.P. 4.6% -2% $57,273,023 +$27,449,059 1,175,796 +92% Vivo Opportunity Fund Holdings, L.P. 30 Jun 2025
BlackRock, Inc. 4.6% -15% $111,424,214 +$5,356,584 1,163,607 +5.1% BlackRock, Inc. 30 Sep 2025
Adage Capital Management, L.P. 5% -45% $53,581,000 +$5,358,100 1,100,000 +11% Adage Capital Management, L.P. 30 Jun 2025
Paradigm Biocapital Advisors LP 3.3% -38% $92,041,065 -$16,034,916 961,164 -15% Paradigm BioCapital Advisors LP 30 Sep 2025
Venrock Healthcare Capital Partners III, L.P. 3.2% -67% $42,793,332 -$30,795,440 639,088 -42% Venrock Healthcare Capital Partners III, L.P. 30 Jun 2025
Commodore Capital LP 2% -58% $56,019,600 -$56,498,400 585,000 -50% Commodore Capital LP 30 Sep 2025
As of 30 Sep 2025, Cidara Therapeutics, Inc. - Common Stock, $0.0001 par value per share (CDTX) has 167 institutional shareholders filing 13F forms. They hold 32,486,735 shares. .

Top 25 institutional shareholders own 76% of the company.

Filer Ownership Nb Shares Share Change % Portfolio % Holdings Value
RA CAPITAL MANAGEMENT, L.P. 11% 3,365,523 0% 4% $322,282,482
Bain Capital Life Sciences Investors, LLC 9.6% 3,020,990 +21% 19% $289,290,002
Point72 Asset Management, L.P. 5% 1,578,069 +3.3% 0.33% $151,115,887
BVF INC/IL 4.5% 1,414,165 +80% 5.5% $135,420,440
Vivo Capital, LLC 4.2% 1,311,425 0% 10% $125,582,058
VANGUARD GROUP INC 3.9% 1,230,666 +27% 0% $117,848,576
BlackRock, Inc. 3.7% 1,165,453 +5.2% 0% $111,603,779
Darwin Global Management, Ltd. 3.2% 997,196 +30% 2.6% $94,992,891
Paradigm Biocapital Advisors LP 3% 961,164 2.7% $92,041,065
VR ADVISER, LLC 3% 946,788 +48% 5.1% $90,664,419
FMR LLC 2.5% 775,533 +613% 0% $74,265,040
STATE STREET CORP 2.5% 772,759 +226% 0% $73,999,402
JANUS HENDERSON GROUP PLC 2.2% 682,901 +9.3% 0.03% $65,363,870
CITADEL ADVISORS LLC 1.9% 593,993 +104% 0.05% $56,880,769
Commodore Capital LP 1.9% 585,000 -50% 2.7% $56,019,600
FARALLON CAPITAL MANAGEMENT LLC 1.6% 508,000 +154% 0.27% $48,646,080
FRED ALGER MANAGEMENT, LLC 1.6% 502,877 0.19% $48,155,502
Soleus Capital Management, L.P. 1.6% 493,811 +6.7% 2.5% $47,287,341
Holocene Advisors, LP 1.5% 487,233 0.11% $46,657,432
UBS Group AG 1.5% 473,554 +166% 0.01% $45,347,531
ADAGE CAPITAL PARTNERS GP, L.L.C. 1.4% 450,000 -59% 0.07% $43,092,000
MAVERICK CAPITAL LTD 1.3% 417,550 0.54% $39,984,588
GEODE CAPITAL MANAGEMENT, LLC 1.3% 404,114 +8.6% 0% $38,706,733
Vestal Point Capital, LP 1.3% 400,000 -20% 1.7% $38,304,000
JENNISON ASSOCIATES LLC 1.3% 396,015 +705% 0.02% $37,922,396

Institutional Holders of Cidara Therapeutics, Inc. - Common Stock, $0.0001 par value per share (CDTX) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (% of par) Investors
2025 Q4 5,372 $1,186,403 +$820,608 22,089.11% 3
2025 Q3 32,486,735 $3,110,319,924 +$679,671,203 9,576% 167
2025 Q2 25,911,048 $1,262,611,204 +$803,273,239 4,871% 106
2025 Q1 9,559,359 $205,909,478 +$57,592,852 2,154% 45
2024 Q4 6,873,669 $183,637,032 +$100,865,297 2,688% 40
2024 Q3 3,308,428 $35,565,026 +$20,361,777 1,075% 27
2024 Q2 1,412,361 $16,863,937 +$16,863,732 1,194% 25